{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:35:29Z","timestamp":1792164929120,"version":"4.4.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1097\/01.wnf.0000168581.97083.9c","type":"journal-article","created":{"date-parts":[[2005,6,17]],"date-time":"2005-06-17T04:01:18Z","timestamp":1118980878000},"page":"120-125","source":"Crossref","is-referenced-by-count":15,"title":["Pergolide"],"prefix":"10.1097","volume":"28","author":[{"given":"Claire","family":"Thalamas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Rajman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lled\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison E","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Blin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Seger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210203","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(02)08520-3","article-title":"Treatment interventions for Parkinsons disease: an evidence based assessment.","volume":"359","author":"Rascol","year":"2002","journal-title":"Lancet"},{"key":"R2-5-20210203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1353-8020(00)00038-9","article-title":"Dopamine agonists: the treatment for Parkinsons disease in the XXI century?","volume":"7","author":"Lledo","year":"2000","journal-title":"Parkinsonism Relat Disord"},{"key":"R3-5-20210203","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00003495-199039030-00009","article-title":"Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinsons disease.","volume":"39","author":"Langtry","year":"1990","journal-title":"Drugs"},{"key":"R4-5-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0014-2999(98)00896-6","article-title":"Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.","volume":"366","author":"Perachon","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"R5-5-20210203","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/mds.870090409","article-title":"Pergolide compared with bromocriptine in Parkinsons disease: a multicenter, crossover, controlled study.","volume":"9","author":"Pezzoli","year":"1994","journal-title":"Mov Disord"},{"key":"R6-5-20210203","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","article-title":"A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinsons disease.","volume":"9","author":"Olanow","year":"1994","journal-title":"Mov Disord"},{"key":"R7-5-20210203","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.53.3.573","article-title":"Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group.","volume":"53","author":"Barone","year":"1999","journal-title":"Neurology"},{"issue":"Suppl 3","key":"R8-5-20210203","first-page":"126","article-title":"Long term efficacy of pergolide monotherapy in early stage Parkinsons disease (PD). One-year interim analysis of a 3-year double-blind randomized study of pergolide versus levodopa.","volume":"15","author":"Lledo","year":"2000","journal-title":"Mov Disord"},{"key":"R9-5-20210203","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.WNL.0000124465.20878.84","article-title":"PEARLS Study Group. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study.","volume":"62","author":"Trenkwalder","year":"2004","journal-title":"Neurology"},{"key":"R10-5-20210203","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mds.20202","article-title":"New concerns about old drugs: valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance.","volume":"19","author":"Rascol","year":"2004","journal-title":"Mov Disord"},{"key":"R12-5-20210203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinsons disease.","volume":"51","author":"Gibb","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R13-5-20210203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality.","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"R14-5-20210203","first-page":"S44","article-title":"Adjuncts to levodopa therapy: dopamine agonists. Neurology. 1998;50:S23-S26. Discussion.","volume":"50","author":"Poewe","year":"1998","journal-title":"Neurology"},{"key":"R15-5-20210203","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0025-7125(05)70112-7","article-title":"Dopamine agonists.","volume":"83","author":"Factor","year":"1999","journal-title":"Med Clin North Am"},{"issue":"Suppl 10","key":"R16-5-20210203","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinsons disease.","volume":"23","author":"Olanow","year":"2000","journal-title":"Trends Neurosci"},{"key":"R17-5-20210203","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00115677-200109991-00005","article-title":"Pharmacological and pharmacokinetic properties of piribedil: a rationale for use in Parkinsons disease.","volume":"9","author":"Allain","year":"2001","journal-title":"Dis Manage Health Outcome"},{"issue":"Suppl 1","key":"R18-5-20210203","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199855001-00002","article-title":"Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinsons disease.","volume":"55","author":"Fariello","year":"1998","journal-title":"Drugs"},{"issue":"Suppl 5","key":"R19-5-20210203","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.50.5_Suppl_5.S17","article-title":"Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.","volume":"50","author":"Chase","year":"1998","journal-title":"Neurology"},{"issue":"Suppl 1","key":"R20-5-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199855001-00001","article-title":"The significance of continuous dopaminergic stimulation in the treatment of Parkinsons disease.","volume":"55","author":"Chase","year":"1998","journal-title":"Drugs"},{"issue":"Suppl 1","key":"R21-5-20210203","first-page":"S176","article-title":"Preventing levodopa-induced dyskinesias. Ann Neurol. 2000;47:S167-S17. Discussion.","volume":"47","author":"Olanow","year":"2000","journal-title":"Ann Neurol"},{"issue":"Suppl 3","key":"R22-5-20210203","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1212\/WNL.45.3_Suppl_3.S28","article-title":"Dopamine agonists in Parkinsons disease.","volume":"45","author":"Wolters","year":"1995","journal-title":"Neurology"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.wnf.0000168581.97083.9c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:40:38Z","timestamp":1785854438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200505000-00005"}},"subtitle":["Multiple-Dose Pharmacokinetics in Patients with Mild to Moderate Parkinson Disease"],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.wnf.0000168581.97083.9c","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}